Citations

Clear

1792 citation(s) found for "Stephanie".

Post Hoc Analysis of PROGRESS: Evaluating the Safety of Atogepant in Participants With Chronic Migraine and Cardiovascular Risk Factors (P10-12.012)
Best, Patricia J.M. , Tassorelli, Cristina , Dabruzzo, Brett , Ferreira, Rosa De Abreu, Smith, Jonathan H., Harriott, Andrea M. , Monteith, Teshamae , Nahas, Stephanie J. , Liu, Yingyi

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202040 Get It

Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial (P12-12.001)
McAllister, Peter , Ma, Julia, Gandhi, Pranav , Smith, Jonathan H., Chalermpalanupap, Natty, Dabruzzo, Brett , Nahas, Stephanie J. , Ailani, Jessica , Singh, Rashmi B. Halker , Lipton, Richard B. , Liu, Yingyi

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000201964 Get It

Adverse childhood experiences and sexual dysfunction in midlife women: Is there a link?
Saadedine, Mariam , Kingsberg, Sheryl A. , Kuhle, Carol L. , Mara, Kristin C. , Kapoor, Ekta , Faubion, Stephanie, Enders, Felicity , Kuhle, Carol, Mara, Kristin, Mara, Kristin C , Faubion, Stephanie S. , Kling, Juliana M. , Kapoor, Ekta

Mayo Clinic

The Journal of Sexual Medicine | April 27, 2023 | Volume: 20 | Issue: 6 | Pages: 792-799

10.1093/jsxmed/qdad053 | PMID 37105936 Get It

Abstract Background One in 3 children has had at least 1 adverse childhood experience (ACE), and ACEs have been associated with multiple medical and psychiatric morbidities in women later in life, including greater menopause symptom burden. Aim To evaluate the association between ACEs and female sexual dysfunction (FSD) in midlife women. Methods A cross-sectional analysis from DREAMS—the Data Registry on Experiences of Aging, Menopause, and Sexuality—was conducted with questionnaires completed by women aged 40 to 65 years who presented to a women’s health clinic at Mayo Clinic in Rochester, Minnesota, from May 2015 to December 2016. History of ACEs was obtained with the validated ACE questionnaire. FSD was assessed by the Female Sexual Function Index and the Female Sexual Distress Scale–Revised. Outcomes The association between ACEs and FSD (defined as Female Sexual Function Index score ≤26.55 and Female Sexual Distress Scale–Revised score ≥11) was evaluated via a multivariable logistic regression model, adjusting for age, menopause status, hormone therapy use, anxiety, depression, relationship satisfaction, hot flash severity, and history of abuse in the past year. Results Women (N = 1572) had a mean age of 53.2 years. Overall 59% reported having at least 1 ACE. When compared with no ACEs, a history of ≥4 ACEs significantly increased the odds of not being sexually active (odds ratio, 1.83; 95% CI, 1.30-2.57; P < .001). Among sexually active women, the proportion of women with FSD increased sequentially as the number of ACEs increased. In the univariate analysis, a history of ≥4 ACEs significantly increased the odds of FSD as compared with no ACEs (odds ratio, 2.12; 95% CI, 1.50-2.99; P < .001). The association remained statistically significant in the multivariable analysis after adjusting for confounders (odds ratio, 1.75; 95% CI, 1.15-2.68; P = .009). Clinical Implications The findings highlight an opportunity for clinicians to screen for ACEs in women with sexual dysfunction and offer appropriate treatment and counseling as indicated. Strengths and Limitations Strengths of the study include the large cohort, the use of validated tools for assessment of ACEs and FSD, and the adjustment for multiple potential confounding factors. Limitations include the cross-sectional study design, recall bias in reporting ACEs and recent abuse, and the low representation of racially and ethnically diverse women in the cohort. Conclusion The study demonstrates an increased risk of sexual inactivity and sexual dysfunction in midlife women who experienced childhood adversity. The sexual dysfunction in women with ACEs seems to be independent of other factors that potentially affect female sexual function in midlife.
Studying the glottal vibration onset and offset using laryngeal high-speed videoendoscopy in connected speech
Naghibolhosseini, Maryam , Henry, Trent M. , Zacharias, Stephanie R. C. , Deliyski, Dimitar D.

Mayo Clinic

The Journal of the Acoustical Society of America | April 26, 2023 | Volume: 153 | Issue: 3_supplement | Pages: A370-A370

10.1121/10.0019205 Get It

Laryngeal high-speed videoendoscopy (HSV) is a powerful tool to study the detailed vibratory characteristics of the vocal folds. The use of HSV in connected speech enables us to study the transitory behaviors of the vocal folds during different vocalizations. The onset and offset of voicing contain critical information about the health and function of the vocal folds. In this work, HSV is used to study how the voicing begins/ends at the laryngeal level at the onset/offset of phonation. HSV data were obtained during production of connected speech from participants with non-pathological voices and patients with different neurogenic voice disorders. The data collection was performed using a Photron FASTCAM mini AX200 high-speed camera coupled with a flexible nasolaryngoscope. The glottal attack time and glottal offset time were measured at the onset and offset of different vocalizations, respectively, from the HSV data. The findings show differences in the onset and offset measures between the two groups of participants. The vocal fold vibratory behaviors will be discussed qualitatively and quantitatively using these measures. The use of HSV in connected speech could help us develop accurate voice assessment procedures to assess the vocal folds function during connected speech.
Staff Successes and Challenges with Telecommunications-Facilitated Patient Care in Hybrid Hospital-at-Home during the COVID-19 Pandemic
Zawada, Stephanie , Sweat, Jeffrey, Paulson, Margaret R. , Maniaci, Michael J. , Zawada, Stephanie K , Maniaci, Michael J , Paulson, Margaret R

Mayo Clinic

Healthcare | April 26, 2023 | Volume: 11 | Issue: 9 | Pages: 1223

10.3390/healthcare11091223 | PMID 37174766 Get It

Technology-enhanced hospital-at-home (H@H), commonly referred to as hybrid H@H, became more widely adopted during the COVID-19 pandemic. We conducted focus group interviews with Mayo Clinic staff members (n = 14) delivering hybrid H@H in three separate locations—a rural community health system (Northwest Wisconsin), the nation’s largest city by area (Jacksonville, FL), and a desert metropolitan area (Scottsdale, AZ)—to understand staff experiences with implementing a new care delivery model and using new technology to monitor patients at home during the pandemic. Using a grounded theory lens, transcripts were analyzed to identify themes. Staff reported that hybrid H@H is a complex care coordination and communication initiative, that hybrid H@H faces site-specific challenges modulated by population density and state policies, and that many patients are receiving uniquely high-quality care through hybrid H@H, partly enabled by advances in technology. Participant responses amplify the need for additional qualitative research with hybrid H@H staff to identify areas for improvement in the deployment of new models of care enabled by modern technology.
The yin and yang of GSM and low sexual desire
Kingsberg, Sheryl A. , Adler, B., Metropoulos, J., Metropoulos, J., Faubion, Stephanie S.

Mayo Clinic

Climacteric | April 21, 2023 | Volume: 26 | Issue: 4 | Pages: 323-328

10.1080/13697137.2023.2194529 | PMID 37083058 Get It

Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
Yadav, Siddhartha , Carneiro, Benedito A. , Pishvaian, Michael J. , Werner, Theresa L. , Sahai, Vaibhav , Lheureux, Stéphanie , Rimkunas, Victoria , Wainszelbaum, Marisa J., Peltz, Gerson, Fei, Kezhen , Kim, Insil , Koehler, María , Yadav, Siddhartha , Sahai, Vaibhav , Yap, Timothy Anthony , Herzberg, Benjamin O. , Fontana, Elisa , Højgaard, Martin , Plummer, Ruth , Lee, Elizabeth K. , Mettu, Niharika B , Coté, Gregory M. , Schonhoft, Joseph D. , Silverman, Ian M. , Fretland, Adrian J. , Ulanet, Danielle , Rosen, Ezra Y. , Cecchini, Michael

Mayo Clinic

Cancer Research | April 14, 2023 | Volume: 83 | Issue: 8_Supplement | Pages: CT018-CT018

10.1158/1538-7445.am2023-ct018 Get It

Abstract Introduction: ATRi and PARPi combinations kill tumor cells via synergistic modulation of complementary DDR pathways but clinical utility is limited by overlapping toxicities. A genome-wide CRISPR-Cas9 screen identified DDR alterations that sensitize tumors to the ATRi camonsertib (cam) plus PARPi. Based on preclinical models, tolerability and efficacy of cam plus PARPi given intermittently at low doses in pts with solid tumors with DDR alterations, including BRCA-mutated PARPi-resistant cancers, was evaluated. Methods: Pts (≥ 18 yrs) with relapsed/refractory (r/r) solid tumors with DDR alterations were treated with cam plus talazoparib (tala), niraparib (nira), or olaparib (ola) in 2 phase I trials (NCT04497116, NCT04972110). An adaptive BOIN design was used to optimize dose/schedule. Endpoints were safety, recommended phase II dose (RP2D), pharmacokinetics (PK), response (RECIST v1.1 [confirmed/unconfirmed], CA 125, or PSA), clinical benefit rate (CBR; RECIST/tumor marker response or treatment duration ≥ 16 wk), and ctDNA molecular response rate (MRR; best reduction in mean variant allele frequency [mVAF] ≥ 50%). Results: As of Nov 2022, 99 pts were enrolled (61 with ≥ 3 prior lines of therapy, 36 PARPi-pretreated); 43, 27, 29 pts in tala, nira, and ola combinations, respectively. Tumors included ovarian (n=20), prostate (n=13), breast (n=17), bile duct (n=3); most common genotypes were ATM (n=26), BRCA1 (n=19), and BRCA2 (n=33). Grade 3+ toxicities included reversible myelosuppression (neutropenia, anemia, and thrombocytopenia in 35%, 28%, and 14% of pts overall; 33%, 16%, and 11% at preliminary RP2Ds), fatigue (3%), and alkaline phosphatase increase (2%). Two pts discontinued treatment due to drug-related toxicity. Forty pts remain on therapy, up to 63 wks. Preliminary RP2Ds: cam 80 mg QD (d 5-7) + tala 0.25 mg QD, 1 wk on/1 wk off; cam 80 mg QD + nira 100 mg QD, 2 d on/5 d off; cam 50 mg QD + ola 100 mg BID, 3 d on/4 d off. As of abstract submission, response rate was 13% in 85 evaluable pts; CBR was 49%. Responders included pts with ovarian (n=6), bile duct (n=2), and breast, pancreatic, and carcinoma of unknown primary (n=1 each) cancers harboring alterations in BRCA1/2 (n=9), IDH1 (n=1), and ATM (n=1). Of 30 evaluable PARPi-pretreated pts, response rate was 23% and CBR was 52%. MRR was 64% (14/22 evaluable); change in mVAF correlated with a change in target lesion size (r=0.63, P=0.001). PK of each drug in the combination was consistent with respective monotherapy PK. Conclusion: Combination of cam plus PARPi at low doses on intermittent schedules was generally well-tolerated with clinical activity in DDR-aberrant tumors, including those pretreated with PARPi. RP2D optimization and translational correlative studies are ongoing. Citation Format: Timothy A. Yap, Siddhartha Yadav, Benjamin Herzberg, Benedito A. Carneiro, Elisa Fontana, Martin Højgaard, Michael J. Pishvaian, Ruth Plummer, Theresa L. Werner, Vaibhav Sahai, Stephanie Lheureux, Elizabeth K. Lee, Niharika B. Mettu, Gregory M. Cote, Joseph D. Schonhoft, Victoria Rimkunas, Ian M. Silverman, Marisa Wainszelbaum, Gerson Peltz, Adrian J. Fretland, Kezhen Fei, Danielle Ulanet, Insil Kim, Maria Koehler, Ezra Rosen, Michael Cecchini. Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT018.
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma
Spencer, Kristen , Pappas, Leontios , Baiev, Islam , Maurer, Jordan R., Bocobo, Andrea Grace, Jain, Apurva, Reyes, Stephanie , Le, Tri Minh , Rahma, Osama E. , Stanton, Jennifer R., DeLeon, Thomas, Roth, Marc, Zhu, Andrew X. , Lennerz, Jochen K. , Iafrate, A. John , Boyhen, Kylie, VanCott, Christine, Roberts, Lewis R. , Lindsey, Stacie , Goff, Laura W. , Mody, Kabir , Shroff, Rachna T. , Kelley, Robin Kate , Javle, Milind , DeLeon, Thomas T, Lennerz, Jochen , Goyal, Lipika , Roberts, Lewis R , Spencer, Kristen , Pappas, Leontios , Zhang, Karen , Jain, Apurva, De Armas, Anaemy Danner , Roth, Marc, Peters, Mary Linton B , Horick, Nora , Borad, Mitesh J. , Goyal, Lipika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 11, 2023 | Volume: 115 | Issue: 7 | Pages: 870-880

10.1093/jnci/djad046 | PMID 37040087 Get It

Abstract Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies. Methods This multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions. Retrospective data were collected on risk factors, pathology, treatments, and survival. Comparative statistical tests were 2-sided. Results Among 1039 patients screened, 847 patients met eligibility (ICC = 611, ECC = 236). Patients with ECC were more likely than those with ICC to present with early stage disease (53.8% vs 28.0%), undergo surgical resection (55.1% vs 29.8%), and receive adjuvant chemoradiation (36.5% vs 4.2%) (all P < .00001). However, they were less likely to undergo molecular profiling (50.3% vs 64.3%) or receive liver-directed therapy (17.9% vs 35.7%), targeted therapy (4.7% vs 18.9%), and clinical trial therapy (10.6% vs 24.8%) (all P < .001). In patients with recurrent ECC after surgery, the molecular profiling rate was 64.5%. Patients with advanced ECC had a shorter median overall survival than those with advanced ICC (11.8 vs 15.1 months; P < .001). Conclusions Patients with advanced ECC have low rates of molecular profiling, possibly in part because of insufficient tissue. They also have low rates of targeted therapy use and clinical trial enrollment. While these rates are higher in advanced ICC, the prognosis for both subtypes of cholangiocarcinoma remains poor, and a pressing need exists for new effective targeted therapies and broader access to clinical trials.
Use of the Revised Second Victim Experience and Support Tool to Examine Second Victim Experiences of Respiratory Therapists
Allender, Erica A, Bottema, Sophia M, Bosley, Christopher, Holst, Stephanie J, Clark, William J., Weaver, Amy L. , Finney, Robyn E. , Bosley, Christopher L., Rivera-Chiauzzi, Enid Y , Clark, William J, Rivera‐Chiauzzi, Enid Y. , Holst, Stephanie J.

Mayo Clinic

Respiratory Care | April 11, 2023 | Volume: 68 | Issue: 6 | Pages: 749-759

10.4187/respcare.10719 | PMID 37041030 Get It

BACKGROUND: Respiratory therapists (RTs) work alongside allied health staff, nurses, and physicians during stressful and traumatic events that can be associated with emotional and physiological implications known as second victim (SV) experiences (SVEs). This study aimed to evaluate SVEs of RTs, including both positive and negative implications. METHODS: RTs within a large academic health care organization across Minnesota, Wisconsin, Florida, and Arizona were asked to participate in an anonymous survey that included the validated Second Victim Experience and Support Tool-Revised to assess SVEs as well as desired support services. RESULTS: Of the RTs invited to participate, 30.8% (171/555) completed the survey. Of the 171 survey respondents, 91.2% (156) reported that they had been part of a stressful or traumatic work-related event as an RT, student, or department support staff member. Emotional or physiologic implications experienced by respondents as SVs included anxiety 39.1% (61/156), reliving of the event 36.5% (57/156), sleeplessness 32.1% (50/156), and guilt 28.2% (44/156). Following a stressful clinical event, 14.8% (22/149) experienced psychological distress, 14.2% (21/148) experienced physical distress, 17.7% (26/147) indicated lack of institutional support, and 15.6% (23/147) indicated turnover intentions. Enhanced resilience and growth were reported by 9.5% (14/147). Clinical and non-clinical events were reported as possible triggers for SVEs. Nearly half of respondents 49.4% (77/156) indicated feeling like an SV due to events related to COVID-19. Peer support was the highest ranked form of desired support following an SVE by 57.7% (90/156). CONCLUSIONS: RTs are involved in stressful or traumatic clinical events, resulting in psychological/physical distress and turnover intentions. The COVID-19 pandemic has had a significant impact on RTs’ SVEs, highlighting the importance of addressing the SV phenomenon among this population.
Abstract 1755: ADAR1-mediated RNA editing of SCD1 links lipid metabolism to gastric cancer drug resistance and self-renewal
Loh, Jia Jian, Lu, Shi‐Xun, Yan, Helen HN, Siu, Hoi Cheong , Ren, Xi , Chan, Dessy , Kam, Max JF, Copland, John A. , Yun, Jing‐Ping , Wong, Tin Lok , Zhou, Lei , Tong, Man , Chen, Leilei , Leung, Suet Yi , Ma, Stephanie

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 1755-1755

10.1158/1538-7445.am2023-1755 Get It

Abstract Targetable drivers governing to 5-fluorouracil and cisplatin (5FU+CDDP) resistance remain elusive due to the paucity of physiologically and therapeutically relevant models. Accordingly, we established 5FU+CDDP resistant intestinal subtype GC patient-derived organoid lines. JAK/STAT signaling and its downstream, adenosine deaminases acting on RNA 1 (ADAR1), are shown to be concomitantly upregulated in the resistant lines. ADAR1 was demonstrated to confer chemoresistance and self-renewal in an RNA editing-dependent manner. WES-seq coupled with RNA-seq identified enrichment of hyperedited lipid metabolism genes in the resistant lines. Mechanistically, ADAR1-mediated A-to-I editing on 3’UTR of stearoyl-CoA desaturase (SCD1) increased binding of KH domain-containing, RNA-binding, signal transduction-associated 1 (KHDRBS1), thereby augmenting SCD1 mRNA stability. Consequently, SCD1 facilitates lipid droplet formation to alleviate chemotherapy-induced ER stress and enhances self-renewal through increasing β-catenin expression. Pharmacological inhibition of SCD1 abrogated chemoresistance and tumor-initiating cell frequency. Clinically, high proteomic level of ADAR1 and SCD1, or high SCD1 editing/ADAR1 mRNA signature score predicts a worse prognosis. Together, we unveiled a novel actionable target to circumvent chemoresistance. Citation Format: Jia Jian Loh, Tin Lok Wong, Shixun Lu, Helen HN Yan, Hoi Cheong Siu, Ren Xi, Dessy Chan, Max JF Kam, Lei Zhou, Man Tong, John A. Copland, Leilei Chen, Jingping Yun, Suet Yi Leung, Stephanie Ma. ADAR1-mediated RNA editing of SCD1 links lipid metabolism to gastric cancer drug resistance and self-renewal [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1755.